Protocol Ledger

NCT03711162 · Phase III · TERMINATED

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Interventional Phase III clinical trial protocol NCT03711162 sponsored by Lakefront Biotherapeutics NV in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-28 Enrollment: 525 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03711162
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)525 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03711162
Protocol FieldVerified Registry Value
NCT IdentifierNCT03711162
Consolidated Lead SponsorLakefront Biotherapeutics NV
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment525 participants (ACTUAL)
Registered Start Date2018-11-28
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI